Study Stopped
The PI is no longer at the University
VDOT and Mobile Payments in Cambodia
Combined Phone Based Video DOT and Mobile Payments for TB Treatment in Cambodia
1 other identifier
interventional
N/A
0 countries
N/A
Brief Summary
This project proposes to develop and pilot a novel smart phone-based intervention to improve tuberculosis (TB) treatment adherence in Cambodia, which integrates video-enabled Directly Observed Treatment (vDOT) with an automated rewards system that transfers mobile money and eventual phone ownership to compliant patients. The results will be of immediate relevance to Cambodia's National TB Control Program (which is partnering with us), the major implementing field partner Operation ASHA (a leading TB-focused nonprofit organization), as well as other TB control programs seeking new alternatives to improving adherence, especially where traditional DOT may be infeasible or costly, and outside the area of TB where adherence to treatment is critical, such as HIV, and will provide key insights into mobile health (mHealth) programs in a setting relevant to other developing countries. The project will involve building new capacity in Cambodia for behavioral research, mHealth,and communications through hands-on training for study staff in-country, and through general training sessions for internal and external stakeholders.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started May 2019
Shorter than P25 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 22, 2018
CompletedFirst Posted
Study publicly available on registry
June 6, 2018
CompletedStudy Start
First participant enrolled
May 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2019
CompletedApril 5, 2024
April 1, 2024
7 months
May 22, 2018
April 3, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Feasibility: % patients correctly using the system
% patients correctly using the system without phone theft, breakages or discrepancies in incentive distribution
6 months
Secondary Outcomes (4)
Missed treatment
6 months
Compliance
6 months
Treatment default
6 months
Cure
5 and 8 months
Study Arms (3)
Control
NO INTERVENTIONParticipants receive current standard of care (DOTS)
VDOT only
EXPERIMENTALParticipants receive daily DOTS treatment with video-enabled mobile monitoring, but also maintain regular supervisory checks
VDOT + mobile money incentives
EXPERIMENTALParticipants receive daily DOTS treatment with video-enabled mobile monitoring supplemented with mobile money incentives, but also maintain regular supervisory checks
Interventions
In VDOT, reminder notifications are sent x minutes prior to the scheduled pill time, and continue every y minutes until the user sends a video of themselves taking their pill via the app. Instructions will be provided in Khmer. The web system has an administrator component whereby a healthcare provider can log in via the Internet to monitor and validate all the videos received that day, and reasons for non-submission.
The VDOT intervention above will be paired with financial incentives in the form of mobile payments in one of the experimental arms.
Eligibility Criteria
You may qualify if:
- Age 21 years or more;
- Diagnosis of TB at healthcare facility (Clinical symptoms consistent with pulmonary TB and sputum test positive);
- Willing to comply with the study procedures;
- Resident at a fixed address within feasible travelling distance to the site and likely to remain resident there for the foreseeable future;
- Willing to have directly observed therapy;
- Willing and able to provide written informed consent in English/Khmer.
You may not qualify if:
- Extra-pulmonary TB or suspected rifampicin resistance;
- Underlying serious chronic diseases (such as liver or kidney disease, active malignancy, poorly-controlled diabetes);
- History of myocardial infarction, congestive cardiac failure, cardiac arrhythmias or family history of Long QT Syndrome;
- Current alcohol or drug abuse;
- Pregnancy;
- Inability to take oral medication or known allergy to one or more of the study drugs.
- Any other significant condition that would, in the opinion of the investigator, compromise the patient's safety or outcome in the trial or lead to poor compliance with study visits and protocol requirements;
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Southern Californialead
- Operation ASHAcollaborator
- National University of Singaporecollaborator
- London School of Hygiene and Tropical Medicinecollaborator
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Joanne Yoong
University of Southern California
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Research Compliance Manager
Study Record Dates
First Submitted
May 22, 2018
First Posted
June 6, 2018
Study Start
May 1, 2019
Primary Completion
December 1, 2019
Study Completion
December 1, 2019
Last Updated
April 5, 2024
Record last verified: 2024-04
Data Sharing
- IPD Sharing
- Will not share